Mr Patrick Gladding. Specialist General Cardiology and Internal Medicine Auckland
|
|
- Ralf Sharp
- 5 years ago
- Views:
Transcription
1 Mr Patrick Gladding Specialist General Cardiology and Internal Medicine Auckland 16:30-17:25 WS #60: Individualising Hypertension Treatment - Intensive or Not? 17:35-18:30 WS #72: Individualising Hypertension Treatment - Intensive or Not? (Repeated)
2 Individualising Hypertension Treatment: Intensive or not? Dr. Patrick Gladding, MBChB, FRACP, PhD Ascot Cardiology
3 Hypertension update Outline New Guidelines Definitions and treatment thresholds Global risk, investigations (Pulse wave velocity) and monitoring (mhealth) Targets SPRINT trial Lifestyle interventions (Functional Foods) Genomics and Personalised Care
4 Secondary causes of Hypertension Aortic coarctation Cushings syndrome
5
6
7
8 Office BP White coat hypertension Ambulatory 24-hr BP (ABPM) Masked hypertension Home blood pressure monitoring Increased granularity White coat hypertension Feedback Dietary/Lifestyle and drug n=1 trials Adherence Personal control JAMA. 2014;312(8): patients 9mmHg SBP reduction with self-mx
9
10
11
12 2 emerging techniques in echo to improve detection of end-organ damage: 1) LV strain; Deformation of the LV vs EF 2) LV mass
13
14 Hypertension update 76 yr old man Supine HTN orthostatic hypotension (~50mmHg) Arterial stiffness indicates lower central BP 14
15
16 JNC 8 Goal for people > 60 yrs should be a SBP < 150, DBP < 90
17 1466 older men and women For fit elderly patients, a high DBP (>90 mm Hg) was associated with a 50% increase in mortality The ultimate goal is personalized treatment so that we can avoid overtreatment of the frail, and undertreatment of the fit. By contrast, for frail elderly patients, a low DBP was associated with a 50% increased risk of dying during 15 year follow-up period
18 9361 patients (age, 50) with SBP of 130 to 180 mm Hg and high cardiovascular (CV) risk One or more: CV disease, CKD EGFR ml/minute/1.73 m2, 10-year Framingham CV risk 15%, or age 75 Patients with diabetes and stroke were excluded. Patients were randomized to either intensive or standard treatment (systolic BP targets, 120 or 140 mm Hg, respectively) The trial was terminated early after median follow-up of 3.3 years The primary composite outcome (MACE) occurred in 5.2% of intensivetreatment patients and 6.8% of standard-treatment patients (P<0.001)
19 First, the results should not be considered a mandate for people to run out and get treated so their blood pressures are below 120. Second, the potential benefits of lowering blood pressure must be weighed against harms. Third, we need more information about the balance of risks and benefits for each person so that the choice can be personalized.
20 The ideal blood pressure for most people is likely to be below 120 mmhg systolic and 75 mmhg diastolic. The 2017 AHA/ACC guideline s recommended treatment goal is to reach office BP levels of less than 130mmHg (systolic) and less than 80 mmhg (diastolic) if pharmacotherapy is commenced.
21
22 Personalised Hypertension Management 80 year old woman seen in clinic. Presenting symptom of presyncope and palpitations. Office BP 190/90 on an ACEi/thiazide combination (Inhibace plus) as well as bisoprolol 2.5mg od. She takes ASA and a statin, has no T2DM, total cholesterol of 3.9, an HDL of 1.3 mmol/l. Creatinine 82 umol/l, caucasian, nonsmoker. Is she well treated? Should treatment be intensified? Is the SPRINT trial relevant? Is there an app for that????
23
24 Insert title of presentation here ABPM shows average BP 135/80 with a precipitous drop at around 1400 (see attached) to BP 105/66, when she often feels unwell. Diastolic BP <65mmHg is BAD
25 Personalised Hypertension Management 80 year old woman seen in clinic. Presenting symptom of presyncope and palpitations. Office BP 190/90 on an ACEi/thiazide combination (Inhibace plus) as well as bisoprolol 2.5mg od. She takes ASA and a statin, has no T2DM, total cholesterol of 3.9, an HDL of 1.3 mmol/l. Creatinine 82 umol/l, caucasian, nonsmoker. Is she well treated? NO. She is overtreated. Should treatment be intensified? NO Is the SPRINT trial relevant? YES and NO SPRINT score calculator NNT 267, NNH 30.
26 Personalised Hypertension Management 80 year old woman seen in clinic. Presenting symptom of presyncope and palpitations. Office BP 190/90 on an ACEi/thiazide combination (Inhibace plus) as well as bisoprolol 2.5mg od. She takes ASA and a statin, has no T2DM, total cholesterol of 3.9, an HDL of 1.3 mmol/l. Creatinine 82 umol/l, caucasian, nonsmoker. Inhibace + is halved I m a different person!
27 ios Android
28 Guidelines take with a grain of salt Increased risk of CV events with very low salt intake Guidelines based on averaging population N Engl J Med
29 Renal denervation therapy SYMPLICITY-3: Renal denervation therapy doesn t work, for unselected patients with HTN Renal artery stenosis
30 Age directed vs Renin directed Rx Individualise Rx based on other comorbidities Spironolactone for Resistant HTN
31
32 J Clin Pharmacol 1994;34:
33 Gladding et al. Personalized Medicine Journal. June 2015,Vol. 12, No. 3, Pages
34
35 Personalised Medicine in practice 35
36 Era of Mobile Health 36
37 Advanced ECG WiFi based ECG Ultraportable, $3,500 Deconvolutes ECG components Advanced pattern recognition, artificial intelligence ECG biological age 37
38 Advanced ECG for general practice Sensitive, high sampling frequency, accurate.
39 Case 43 year old man with dyspnoea, BP 220/140
40 Case
41 British Journal of General Practice 2007; 57: BMJ 1996;312:222 41
42 A-ECG LVSD Sensitivity 93-95%, Specificity 95% Southern X reimbursed
43
44 Conclusion Hypertension is common, often called the Silent Killer Requires personalised Care taking into account Global risk Age and comordities Guidelines not always applicable to the individual patient Emerging technologies for investigation of end-organ disease Lifestyle, diet, prevention paramount Functional foods Feedback, mhealth, Internet of Things (IoT) Limited new drug treatments, or procedures though these will be targeted Emerging role of genomics (not yet fully advocated)
45 Interactive Session: Hypertension and Personalised Care Dr. Patrick Gladding, MBChB, FRACP, PhD
46 Case: 26 year old with HTN on home BP monitor Ubiquitous home BP monitoring Checked BP on friend s mother s home BP machine Measurement high ABPM 169/101 No other PMHx Maternal Grandparents had HTN, Gfather had ESRF and HD Normal diet, no illicit drugs Mother did not have pre-eclampsia Normal FBC, Cr, TSH. 46
47 Case: 26 year old with HTN on home BP monitor What investigations would you order? 1. Urinalysis sediment, microalbumin/cr ratio 2. Renin/Aldosterone levels 3. Echocardiogram 4. Renal artery USS 5. All of the above 47
48 Case: 26 year old with HTN on home BP monitor What investigations would you order? 1. Urinalysis sediment, microalbumin/cr ratio 2. Renin/Aldosterone levels 3. Echocardiogram 4. Renal artery USS 5. All of the above 48
49 Case: 26 year old with HTN on home BP monitor Differential diagnosis for his age Secondary hypertension much more likely from structural reasons e.g. coarctation, PCKD, but acute renal injury, nephritis but also endocrine (hyperaldosteronism) FHx PCKD? Hereditary HTN 49
50 Case: Value of ubiquitous home BP monitoring Checked BP on friend s mother s home BP machine Measurement high ABPM 169/101 USS right renal hydronephrosis ACEi -?nephrectomy 50
51 Case: 56 year old man with longstanding hypertension 56 year old man with longstanding hypertension GORD, dyslipidaemia, TIA 2014?, abnormal LFTs - 3-4L beer/day Palmar desquamation reaction to indapamide ABPM average BP 145/87, whilst on Candesartan 16mg od Renal USS no renal artery stenosis, post void residual 80mls Echocardiogram: Mild basal septal hypertrophy Renin 744 (4 46), Aldosterone 134 (60 1,000) on ARB
52 Case: 56 year old man with longstanding hypertension
53 Case: 56 year old man How would you manage him? 1. Renin directed Rx - Bb 2. Add bendrofluazide 3. Add amlodipine 4. Counsel regarding EtOH 5. 1 or 3, and 4 Spironolactone for Resistant 53 HTN
54 Case: 56 year old man How would you manage him? 1. Renin directed Rx - Bb 2. Add bendrofluazide 3. Add amlodipine 4. Counsel regarding EtOH 5. 1 or 3, and 4 54 Spironolactone for Resistant HTN
55 Case: 56 year old man with longstanding hypertension Renin is a red herring, cannot be relied upon whilst taking antihtn meds, especially RAAS blockers Renin is also elevated in chronic EtOH Indapamide is a thiazide-like diuretic, as is bendrofluazide?class effect with desquamation Age on the cusp of the NICE guidelines so could get ACEi (<55yrs) or CCHB (>55yrs) however the big problem is in the ABPM
56 Case: Value of 24hr ABPM and diurnal measures Focus on alcohol Worrying diastolic nadir 40mmHg
57 Case: 56 year old man abstaining from alcohol
58 Case: 61 year old GP 61 year old GP, Hx of HTN on Rx 12L ECG normal AECG abnormal/cad and biological age Coronary angiogram mild-moderate CAD 58 Journal of Hypertension 2014, 32:
59 Case 61 year old GP What are the red arrows pointing to? 1.Acute coffee intake 2.Conn syndrome 3.Work stress 4.Normal diurnal variation 5.Phaeochromocytoma
60 Case: 61 year old GP What are the red arrows pointing to? 1.Acute coffee intake 2.Conn syndrome 3.Work stress 4.Normal diurnal variation 5.Phaeochromocytoma
61 Case 61 year old GP Work stress is associated with HTN Concurrent CAD Rx to lower target? Manage causes of stress, mindfulness 61 Journal of Hypertension 2014, 32:
62 Case: 56 year old wife of GP Emotional stress ABPM BP 166/97 (Grade II HTN) Was on Amlodipine 5mg Drug withheld 2 weeks: Renin 22, Aldo N Green mussel extract, celery extract J Clin Hypertens (Greenwich) Jan; 16(1): Journal of Hypertension 2014, 32:
63 Case: 56 year old wife of GP What is the next course of action? 1.Increase dose of CCHB 2.Bb 3.ACEi or ARB 4.Diuretic 5.Spirinolactone 63 Spironolactone for Resistant HTN
64 Case: 56 year old wife of GP What is the next course of action? 1.Increase dose of CCHB 2.Bb 3.ACEi or ARB 4.Diuretic 5.Spirinolactone 64 Spironolactone for Resistant HTN
65 Case 56 year old wife of GP Emotional stress Was on Amlodipine 5mg ABPM BP 166/97 Renin 22, Aldo N Green mussel extract, celery extract Px Chlorthalidone 12.5mg od Pranayama Pranayama J Clin Hypertens (Greenwich) Jan; 16(1): Journal of Hypertension 2014, 32:
66 Case: 48 year old woman 48 year old woman with depression on Venlafaxine 225mg Mild dyslipidaemia Prior Hx of right sided breast cancer, partial mastectomy FHx of premature stroke Office BP 145/99 Normal Cr, ECG, renin/aldosterone ratio 66
67 Case: 48 year old woman How would you better define risk in view of BP? Advanced lipids Lp(a) CIMT CAC ETT CTCA 67
68 Case: 48 year old woman How would you better define risk in view of BP? Advanced lipids Lp(a) CIMT CAC ETT CTCA 68
69 Case: 48 year old woman What is the cause of her mild hypertension? 69
70 Case: Drug induced HTN 48 year old woman with depression started Venlafaxine, BP 145/99 Genomics indicated ADE WiFi BP max 133/95 70
71 Case:29 year old woman 29 year old woman, otherwise well, father adopted Normal weight, no EtOH No added salt, good sleep quality Office BP 140/90 on OCP 71 Journal of Hypertension 2009, 27:
72 What would you do next? 1. Stop the OCP, alternative Rx and retest her BP hr ABPM 3. Renin/Aldosterone 4. Renal USS 5. Renal denervation therapy
73 What would you do next? 1. Stop the OCP, alternative Rx and retest her BP hr ABPM 3. Renin/Aldosterone 4. Renal USS 5. Renal denervation therapy
74 Case: Incidental genomics 29 year old woman, otherwise well, father adopted Office BP 140/90 on OCP ABPM 132/85 deltaf508 carrier Genetic counselling Prenatal screening 3-4 cups of coffee per day associated with increased risk of MI and HTN in poor metabolisers Journal of Hypertension 2009, 27:
75 Case 54 year old man 54 year old man presents with MI HTN with known hypertensive retinopathy, mild-mod LVH on Echo BP 217/119 in 2014, started on Felodipine 10mg od Smoker Occasional methaphetamine user BP 170/90 on chlorthalidone 12.5mg od Moderate CAD on coronary angiography ASA/Ticagrelor/Statin/Bb/Chlorthalidone
76 Case 54 year old man - Potassium Renin <2 (4 46), Aldosterone 600 (60 1,000) Felodipine 10mg od Losartan + Thiazide 3.5 MI 3.4 F/up clinic Chlorthalidone stopped Atypical CP, dyspnoea Admitted to hospital TnI <15 K supp Atypical CP, dyspnoea Admitted to hospital Dx GORD Spironolactone Took P went to ED 2.9
77 Case: 54 year old man What is the diagnosis? 1.Acute coffee intake 2.Surreptitious thiazide use 3.Conn syndrome 4.Methaphetamine related hypokalaemia 5.Phaeochromocytoma
78 Case: Conn Syndrome What is the diagnosis? 1.Acute coffee intake 2.Surreptitious thiazide use 3.Conn syndrome Saline suppression test Renal vein sampling 4.Methaphetamine related hypokalaemia 5.Phaeochromocytoma
79 Thank you
Hypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationManagement of Hypertension and Consequences of non-compliance. Colin Edwards
Management of Hypertension and Consequences of non-compliance Colin Edwards CARDIOLOGIST AHG May 2016 Outline 1. Consequences of poorly controlled hypertension 2. BP targets and anti-hypertensive drugs
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationPersonalised Medicine in Practice. Dr. Patrick Gladding MBChB, PhD Cardiologist, NSH
Personalised Medicine in Practice Dr. Patrick Gladding MBChB, PhD Cardiologist, NSH 1 Challenges of medicine in 21 st C Increasing demand Aging population Constrained, limited resources Inefficiency and
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationHYPERTENSION CHAT with Colin and Ted AUG 2015
HYPERTENSION CHAT with Colin and Ted AUG 2015 INTRODUCTION Hypertension has challenged famous physicians for centuries. 1733 - Clergyman Stephen Hales made the 1 st published measurement of blood pressure
More informationRESISTANT HYPERTENSION
RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationColin Edwards. Cardiologist Auckland Heart Group Waitemata Health
Colin Edwards Cardiologist Auckland Heart Group Waitemata Health August 2011 BP MEASUREMENTS measured seated mean of 2 or BP recordings at least 2 visits 2 x risk of developing true hypertension Size of
More informationPatrick Kay, General and Interventional Cardiologist Auckland or healthpoint.co.nz
Patrick Kay, General and Interventional Cardiologist Auckland ipatkay@hotmail.com or healthpoint.co.nz Rotorua 2015 Rotorua 2015 Graphical example of true mean and variation, and of regression to the
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationPersonalised Cardiovascular medicine: Integrating therapeutics and diagnostics. Dr. Patrick Gladding, MBChB, PhD Cardiologist, WDHB
Personalised Cardiovascular medicine: Integrating therapeutics and diagnostics Dr. Patrick Gladding, MBChB, PhD Cardiologist, WDHB 2 3 4 Era of Mobile Health 5 Wireless Telemedicine 6 Increased sensitivity
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHow do we diagnose hypertension today? Presentation Subtitle
How do we diagnose hypertension today? Presentation Subtitle Renata Cífková Case 1 JM, a 64-year-old lady referred to our center because of undesirable effects of her antihypertensive medication Personal
More informationCKD & HT. Anne-Marie Angus
CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major
More informationColin Edwards. Cardiologist Auckland Heart Group Waitemata Health
Colin Edwards Cardiologist Auckland Heart Group Waitemata Health AUG 2012 Introduction Case Summary BP MEASUREMENTS measured seated mean of 2 BP recordings per visit at least 2 visits Diet Exercise Weight
More informationHYPERTENSION. Introduction. Colin Edwards Cardiologist AHG and WDHB
HYPERTENSION Introduction Colin Edwards Cardiologist AHG and WDHB June 2014 Disclosures FIONA STEWART Advisory Board Pfizer, AstraZeneca Meetings - AstraZeneca, MSD COLIN EDWARDS Meetings - AstraZeneca
More informationNew Hypertension Guidelines. Kofi Osei, MD
New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationPractical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets
Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets Robert J. Herman University of Calgary herman@ucalgary.ca Conflict of Interest Disclosure
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationOverview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar
Overview 1. Why hypertension is important? 2. What are basic principles in treatment? 3. Different ways of measuring 4. Hypercholesterolemia NOT A REPETION OF LOCAL GUIDELINE CVD risk factors? Non modifiable
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationIncidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
More informationApproach to Management of Hypertension. Prof. Abdulkareem Al-Suwaida, MD, FRCPC, MSc
Approach to Management of Hypertension Prof. Abdulkareem Al-Suwaida, MD, FRCPC, MSc 442-2018 Objectives of The Lecture Hypertension in KSA New definitions of hypertension Understand how to diagnose hypertension
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationHow do I investigate suspected secondary hypertension? Marie Freel RCP Update in Medicine 23 rd November 2016
How do I investigate suspected secondary hypertension? Marie Freel RCP Update in Medicine 23 rd November 2016 World beaters..! Michel Joffres et al. BMJ Open 2013;3:e003423 Hypertension often poorly controlled
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationHypertension Controversies: SPRINTing to New Goals
Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationEvaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016
Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationHypertension Update. Faculty/Presenter Disclosure
Hypertension Update Who Gives a CHEP About Targets? Faculty/Presenter Disclosure Presenter: Raj Padwal Relationships that may introduce potential bias and/or conflict of interest: Grants/Research Support:
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationThe State of Hypertension in NZ in 2010 personal view
The State of Hypertension in NZ in 2010 personal view Patient referred to medical clinic Dear Dr, Please see this man with resistant hypertension 50 year old European male Blood Pressure on current meds
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationBrent M. Egan, MD Professor of Medicine USCSOM Greenville
Contemporary Management of Uncontrolled and Treatment Resistant Hypertension Brent M. Egan, MD Professor of Medicine USCSOM Greenville Disclosures (past 3 years): Honoraria: BCBSSC, Medtronic Grant Support:
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationBlood Pressure. Michelle Bertram- Nephrology- OBH
Blood Pressure Michelle Bertram- Nephrology- OBH Hypertension- how common? 29-30% white adults 46-51% uncontrolled Diagnosis Two or more properly measured BP s after an initial screen NICE guidelines also
More informationCardiovascular risk factor appraisal art or science?
Cardiovascular risk factor appraisal art or science? Prof. Philip MacCarthy BSc MBChB (Hons) PhD FRCP Consultant Cardiologist Bupa Cromwell Hospital Clinics: Wednesday & Friday PM/Evening What are we trying
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More information